International Journal of Radiation Oncology, Biology, Physics 1999: Vol 43 Index

9 Pages·1999·2 MB·English

AUTHOR INDEX
AUTHOR INDEX

Schmidt
schmutz
Schneider
Schomberg
Schulsinger
Schultheiss
Schultz, D. J
Schulze, K
Sschweinturth
ghunathan, P Scorsetti, M
Scou, C. B
1009 Senan, S., 51
Seong, J
Shatron
Shakil
sham, ft
Shamsa
Shapira
Sharma, M
Sharpe, G
Sheldon, J
Shelley. W
Reynolds Shepherd, |
Rheaume Shimamura
Richie, J Shinzato S 777
Rietveld Shiomi, H., 989
Roa, W Shipley W. I
Robins, J Shirato, H., 7
Rodebaugh Shockley
Shvero, J
Sido, M
Siochi, R
Skladowski
Slosarek, K
Smith, J. G
Smith, N. B
Rotman, M Smith, T
Rouzaud, M Smitt, M M
Rowbottom Sneed, P M
Rubens, D Séderman an Putten, W
Rudoler, S Sohn, J. W van Putten, W
Ruifrok, A Solin, | Rhoon
Russell, A Song, ¢( Somsen <
Russel K Ss. O
Russo, ( M
Ryan \ Souham!
Speiser, B
Sabattier Spencer, W
Ȏ Sqguiban, (
Ȏ Stallings
Storey. M
dé
SY akumoto Stoutter
S alter, M Strang
Ss amson Stroom
Sandler Suh, ¢
Ȏ inford Suh, J. H.. 103
Si antana Sulkes, A., 1009
Si irgent Sunshine, J. H., 24
Sz iwada, S Suzuki, K., 783
Ȏ iwamura 5 Suzuki, M
Sawyer, T. E., 965 Svane, G
H
Saxena, V. A.. 88 Svensson
ara, W. M
Scarpati, D., 497 Swindell Waterman, |
Schepps, B., 241 833 Syndikus Wazer, D. I
Popow Ski Y Schiza, S., 107 Webb, S
Porter, § Schleck, C. D., 817 Takagaki, M 3] Weber, D., 971
Schlienger, M., 25 Takemoto, C.. 601 Werner-Wasik, M
West, ( M I 481 Wygoda, A., 101 Yount, G., 399 Zamorano, L. J., 977
White, R. M., 940 Youssef, Y. M., 115 Zee, B., 39
Wijnmaalen \ Y akar, D. A., 9 Yu, Y., 647 Zehr, E. M., 715
Wilkins, P R y amazaki, H., 989 Yue, N., 447 Zelefsky, M. J., 235, 437
Wimbi sh K Y ancik, R., 3 Zhang, J. B. Y., 647
Wehre H.R Y ang, C.-C. J., 663 Ziaja, E. L., 235
Worotniuk, V Y ates, J a Zietman, A. L., 700, 715
K 155 Y oshida, K., 989 Zagars, G. K., 379 Zubizarreta, E., 1061
Wust Pp y Yoshinaga, M., 777 Zamboglou, N., 653 Zwacka, R., 171
H vd Alll
Hodgkin's dise
Hormone therapy
Human) squam«
radiotherap
mploy
idoesophag
$75
Immune
IMRT
In vitro, 405
In vivo, 849
In vivo dosimetry, 245
neck neopla
wiLoOppoorryp h
1><
tle
Hemoglobin concentration, 101 Keratinocytes, 41821]
Hepatocellular carcinoma, 393 Kinetics
ary prostate cance! Kurtosis, 183
nicotinamide, 627 Prostate seed implant, 647 Rigid body transformation, 663
NMR, 627 Prostate specific antigen, 587 Rotating gamma unit, 689
Node-positive, 261 Prostatectomy, 735
attee cardia: c eeffffeecctts . 7445 Ne vasive immobilization, 45-5 Prostate-specific antigen
| ate radiationmn eeffffeeccttss, 839r l N nall, cell lung cancer, 965 z Prostatic brachytherapy
ate radiation-induced damage mal tissue complication proba Ptervgium. 597
635 PTV margin, 905 Scattered radiation
ate rectal complications, 385 al tissues Pubic arch, 583 SCCVII tumors
illiefor’s, e18s3 25 -ulmonary complication, 489 Schwannoma, 5S4455
near accelerator zi Pulmonary function. 489 Seed impl wt 67
| '
ine‘ ar accelerator erea diosurgery Piull sed 1 < dose ratet, 9595 , 9 71 Sensitivity analy, sis, 64 7
$45
: Setup deviation, 905
inear quadratic model, 199, 601 Q Setup reproducibilit] y, 211
1O83 ; Online control, 927 Single ph' oton emission tomogra
inear-quadratic model, 639 Optimization, 647, 671
>
ocal control, 26] : Optimization algorithms, 663 Quality assurance
ocal neoplasm yrs a9 Organ motion, 719, 905 Quality control, 92 Skin, 635
ocal recurrence, 26, 341 Outcome process assessment, 115 Quality of life, 73 Skin neoplasms
cal survival analysis, 1] Oxygen enhancement ratio. 1083 Quantitative radiobiology Small cell lung cancer, 39
illy advanced, 261 Oxygenation, 367, 41123 Solid-state phantoms, 653
mg-term morbidity Squamous cell carcinoma, 505
ong-term results, 329
Sr beta irradiation, 597
ow dose rate, 95
Stage IIIB, 763
icanthone, SY
R3230 AC tumor, 859 Static
une. 505 p53- , 399 Radiation. 405. 715. 1001 Statistical 1 models, | 1
Lung cancer, 893 = 2 -
' _ p53, 607 Radiation dosimetry, 1135 Stereotactic radiosurgery, 305
ymphocyte predominance 29 ‘ : =" ee ea 549. 689
Paclitaxel, 1001 diation ionizing, 73
Palliation. 51] Radiation Oncology Stereotactic radiotherapy, 199
Paranasal sinuses Radiation theray \ 193 990 9?
517. $97. 601. 607 35 Subcutaneous fibrosis, 635
Radiation-induced catar 2 Superficial hyperthermia, 68|
Magnetic resonance Radiation-induced fibrosis Surgery, /39
Magnetic resonance Radiation-induced grow actors Surgica
PDR. 97 Q77 Survival
Mammmooggrraapph y ic tumors Radical parametrect
M inIpDoO wer,» I1t0 7 Radiobiolo1 gical m«
Med~idiaassttiir num 965 perfusion
Mediumo-r dose-srea-traet,e. 1100661] Perioperative radioth,e rapy. 989 adioimmunotherapy
Melde. udlullolobbll5 asttoommaa, 2277 99 Peripheral nerve, 1103 RI adioluminography
Melen ingigoiommaa,, 3232 ! Radiomodification
Melteatsatsattaitcic ffaaiilluurree,. 2? ¢ an Radiosensitivity, .1 9] angential
Mice, 867
Radiosensitization, 405, 413 3 arget margins
Micronuclei, 1125 Pions, 47 Radiosurgery, 299, 31 32 : get motion
Micronucleus. 431 ' ; - -
licronucleus, 431] Pleural mesothelioma 549
Microwave antenna, 681 Radiotherapy
Mild temperature hyperthermia ;
859
Mobile shield, 1037
Thermal dosimet
Monte ¢ Thermoplastic mas
Morbidity <diction outcome. 313 2 959, | ) Thoracic radiotherap
MR i 7
issavs. 48] 1049. 1065. | 1. | | 3D conformalra c
MRI Preoperative adjuvant chemother Radiotherapy | glottic car 3-D matching, 66
MRI thermometry apy, 1043 3DCRT, 475
Multileaf collimator Preoperative adjuvant radiatior Radiotherapy t ment p ¢ hree dimens
Mycosis fungoides, 1043 R22
Mylyoo cardiatlal iinnffaarrccttiioonn, Preoperative radiation. 5_3— Rando. mized study —_— Th; ree-dimensional conformal ra
Primitive neuroectodermal tumor il cancer, 537, 104 diotherapy, 79
} Rectal dosimetr\ 2 Three-dimensional radiation ther
Proctitis, 81 Recurrence, 79 ipy planning, 571
Prognosis, 379 Reirradiation, 789 Three-dimensional treatment plan
Nasopharyngeal carcinoma, 273, Prognostic factors, 2 Relative biological effectiveness ning, 437
607 Prostate, 67, 715 639 Chrombopoietin, 867
Nasopharynx, 995 Prostate brachytherapy, 583, 1021 Remote afterloader, 1055 TLDs, 245
Necrosis, 849 Prostate cancer, 57, 2 ; Reoxygenation, 367 TNM classification,
Neoadjuvant chemotherapy, 517 565, 587, 7 5 Repair proteins, 191 Tolerance, 1021
Neoplasms, 505 Prostate carcinoma, 727 Resection margins, 1029 Topical nitrogen mustard, 951]
Neurilemmoma, 545 Prostate implants, 447 Resistivity, 849 Topograms, 455
Neuropathy, 305 Prostate neoplasms, 47, 571, 707 Retinoids, 367 Topoisomerase II, 89
1195
Total body irradiation, 497 Treatment volume, 587 Uniformity, 183 Whole brain radiotherapy, 549
Total skin electron beam therapy Treatment-induced, 817 Workforce, 1075
95] TRUS, 375, 579, 583
Toxicity, 293 Tumor, 413, 849
Training programs, 833 Tumor blood flow
Transcatheter arterial chemoembo Tumor markers, 73
: nes Vasomodulators, ¢
lization, 393 Tumor necrosis factor alpha \
; . erapamil, 623
Transforming gr 1 f I l TNFa), 839 \ f _
(TGFB-1), 83‘9 Tumor pO,, 859 olume analysi<s8 , 72 Xenograft, 617
. _— 7 volumetry,
iransitional-cell carcinoma Tumor resistance, 108
[ransperineal implants, 565
ransrectal ultrasound, 375, 579
S83
Treatment out
Treatment plan eva 1143 Ultrasound, 719 Well-type ionization chambers Z-dependent dose—volume histo
Treatment verificatio } Ultrasound hyperthermia, 21 653 gram, 1143